DiCE Molecules SV LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From DiCE Molecules SV LLC
Mark Rowen, associate director of business development at Genentech, talks to Scrip at BIO-Europe Spring 2018 about the company's recent technology deals with DiCE Molecules and FinnGen.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2017.
The German pharma options potassium channel modulator technology from Autifony and partners with Roche on immunological approaches to irritable bowel syndrome. Roche unveils discovery pacts with Confo and DiCE.
Emerging Company Profile: New technology platform aims to apply directed evolution to identify small molecule candidates, much like large molecules like monoclonal antibodies are developed, which the Calif. start-up thinks can bring oral drugs to new fields.
Drug Discovery Tools
- Molecular Diversity
- Drug Discovery Tools